Mission Bio

/ 400 E Jamie Ct, Suite 100

CA 94080 South San Francisco

US

Mission Bio

Foundation date

2012

Sector

#Pharma

Subsector

Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. Discover how Tapestri enables accurate characterization of your cell and gene therapy candidates for safer and more effective therapeutic strategies. We partner with pharma and biopharma companies across advanced therapy development programs to implement proven single-cell multi-omics capabilities into discovery, translational, and clinical research efforts. Learn more about our Pharma Assay Development services.

Latest news

  • Kurma Partners achieves first close of new EUR 250 million Biofund IV

    Thursday October 3rd 2024

  • Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety

    Tuesday October 1st 2024

  • Obulytix appoints Dr. Kristof Van Emelen as Chief Executive Officer

    Tuesday October 1st 2024